Spyre Therapeutics (SYRE) to Release Quarterly Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Spyre Therapeutics Stock Performance

NASDAQ:SYRE opened at $36.60 on Thursday. The firm’s 50-day moving average is $33.14 and its 200-day moving average is $25.01. Spyre Therapeutics has a 52-week low of $10.91 and a 52-week high of $37.98. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -16.71 and a beta of 3.15.

Analysts Set New Price Targets

SYRE has been the topic of several recent research reports. JonesTrading raised Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a report on Monday, December 1st. BTIG Research restated a “buy” rating and issued a $70.00 price target on shares of Spyre Therapeutics in a research report on Friday, January 16th. Wall Street Zen raised Spyre Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. Finally, Citigroup started coverage on Spyre Therapeutics in a report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Spyre Therapeutics currently has an average rating of “Buy” and a consensus price target of $53.88.

Insider Buying and Selling

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $32.80, for a total transaction of $492,000.00. Following the transaction, the chief executive officer directly owned 657,540 shares in the company, valued at approximately $21,567,312. This represents a 2.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 45,000 shares of company stock valued at $1,387,500 in the last three months. 15.43% of the stock is owned by company insiders.

Hedge Funds Weigh In On Spyre Therapeutics

Large investors have recently bought and sold shares of the business. RTW Investments LP grew its holdings in Spyre Therapeutics by 15.2% during the 4th quarter. RTW Investments LP now owns 4,171,996 shares of the company’s stock worth $136,675,000 after acquiring an additional 550,000 shares during the period. State Street Corp boosted its position in shares of Spyre Therapeutics by 26.8% in the 4th quarter. State Street Corp now owns 2,262,839 shares of the company’s stock worth $74,131,000 after purchasing an additional 477,633 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Spyre Therapeutics by 13,969.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,829,009 shares of the company’s stock worth $59,918,000 after purchasing an additional 1,816,009 shares during the period. Geode Capital Management LLC grew its stake in shares of Spyre Therapeutics by 35.4% during the fourth quarter. Geode Capital Management LLC now owns 1,659,140 shares of the company’s stock worth $54,362,000 after purchasing an additional 433,987 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Spyre Therapeutics by 8.4% in the third quarter. Wellington Management Group LLP now owns 1,640,312 shares of the company’s stock valued at $27,492,000 after purchasing an additional 126,834 shares during the last quarter. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.